Global Cardiac Resynchronization Therapy Market is estimated to value over USD 4.8 billion by 2026 end and register a CAGR of over 4% during the forecast period 2019 to 2026. The population across the world is rapidly ageing, due to increasing life expectancy and reduced birth rates. As per the report by the United Nation’s Economic and Social Commission for Asia and the Pacific (ESCAP), the Asia Pacific geriatric population in the was around 615 million in 2015, for more than half of the world’s total aged population. It is predicted that by 2050, the Asia-Pacific will account for almost 2/3rd of the world’s geriatric population. The rising geriatric population is the major reason behind the increase in the cases of cardiovascular and heart failure. As per the American College of Cardiology, cardiovascular disease (CVD) recorded for over 800,000 deaths in the U.S in 2016. Coronary heart disease (CHD) held the majority of cardiovascular disease deaths, followed by heart failure and stroke. In 2017, according to the European Heart Network, cardiovascular disease (CVD) is responsible for over 4 million deaths in Europe. Moreover, the sedentary lifestyle leads to a high prevalence of high cholesterol, high alcohol consumption, high blood pressure and obesity which together contributes to the high incidence of cardiovascular diseases. Such unhealthy lifestyle choices are leading to a high cardiac resynchronization therapy market growth in cardiovascular disease cases. The growing awareness of the treatment options is also expected to drive the market. Rising Geriatric Population is the Key Factor for the Proliferation of the Market An important factor bolstering the cardiac resynchronization therapy market growth of this industry is the rising volume of aged patients across the world. They are more prone to illness and are predicted to need the therapy products used for resynchronization to facilitate healthy heart activity. Apart from the failure of heart, certain conditions like congenital heart disease, atrial fibrillation and arrhythmias also demand the utilization of these devices. For the sake of promoting the development and raising awareness in this market, agencies like the European Heart Rhythm Association and the European Society of Cardiology have formulated guidelines. These guidelines have been documented into three sets depending on the patient type to provide an accurate decision. Geographically, the North America region is projected to account the largest cardiac resynchronization therapy market share over the forecast period owing to an increasing growth of geriatric population suffering from cardiac dysfunction and rising number of approvals by the U.S. FDA for new products. North America held over 30.0% of the global cardiac resynchronization therapy market share in 2016. Europe held a significant share and is anticipated to exhibit a profitable growth with CAGR of over 7% over the next decade. Higher restraints are being implemented by the healthcare agencies toward product approvals, research and development and safety guideline follow-up, are expected to drive the cardiac resynchronization therapy market growth. Key market players included in the cardiac resynchronization therapy industry are Medtronic Plc, Abbott Laboratories, Boston Scientific Corp., Biotronik, Medico S.P.A, Microport Scientific Corp. Global Cardiac Resynchronization Therapy Market Segmentation: By Type · Cardiac Resynchronization Therapy Defibrillators · Cardiac Resynchronization Therapy Pacemakers By End User · Hospitals & Cardiac Centers · Ambulatory Surgery Centers By Region · North America · Europe · Asia Pacific · Rest of the World FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global cardiac resynchronization therapy market by type, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe and the rest of the world To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com
Global Cardiac Resynchronization Therapy Market is estimated to value over USD 4.8 billion by 2026 end and register a CAGR of over 4% during the forecast period 2019 to 2026.
The population across the world is rapidly ageing, due to increasing life expectancy and reduced birth rates. As per the report by the United Nation’s Economic and Social Commission for Asia and the Pacific (ESCAP), the Asia Pacific geriatric population in the was around 615 million in 2015, for more than half of the world’s total aged population. It is predicted that by 2050, the Asia-Pacific will account for almost 2/3rd of the world’s geriatric population. The rising geriatric population is the major reason behind the increase in the cases of cardiovascular and heart failure.
As per the American College of Cardiology, cardiovascular disease (CVD) recorded for over 800,000 deaths in the U.S in 2016. Coronary heart disease (CHD) held the majority of cardiovascular disease deaths, followed by heart failure and stroke. In 2017, according to the European Heart Network, cardiovascular disease (CVD) is responsible for over 4 million deaths in Europe. Moreover, the sedentary lifestyle leads to a high prevalence of high cholesterol, high alcohol consumption, high blood pressure and obesity which together contributes to the high incidence of cardiovascular diseases. Such unhealthy lifestyle choices are leading to a high cardiac resynchronization therapy market growth in cardiovascular disease cases. The growing awareness of the treatment options is also expected to drive the market.
Rising Geriatric Population is the Key Factor for the Proliferation of the Market
An important factor bolstering the cardiac resynchronization therapy market growth of this industry is the rising volume of aged patients across the world. They are more prone to illness and are predicted to need the therapy products used for resynchronization to facilitate healthy heart activity. Apart from the failure of heart, certain conditions like congenital heart disease, atrial fibrillation and arrhythmias also demand the utilization of these devices.
For the sake of promoting the development and raising awareness in this market, agencies like the European Heart Rhythm Association and the European Society of Cardiology have formulated guidelines. These guidelines have been documented into three sets depending on the patient type to provide an accurate decision.
Geographically, the North America region is projected to account the largest cardiac resynchronization therapy market share over the forecast period owing to an increasing growth of geriatric population suffering from cardiac dysfunction and rising number of approvals by the U.S. FDA for new products. North America held over 30.0% of the global cardiac resynchronization therapy market share in 2016.
Europe held a significant share and is anticipated to exhibit a profitable growth with CAGR of over 7% over the next decade. Higher restraints are being implemented by the healthcare agencies toward product approvals, research and development and safety guideline follow-up, are expected to drive the cardiac resynchronization therapy market growth.
Key market players included in the cardiac resynchronization therapy industry are Medtronic Plc, Abbott Laboratories, Boston Scientific Corp., Biotronik, Medico S.P.A, Microport Scientific Corp.
Global Cardiac Resynchronization Therapy Market Segmentation:
By Type
· Cardiac Resynchronization Therapy Defibrillators
· Cardiac Resynchronization Therapy Pacemakers
By End User
· Hospitals & Cardiac Centers
· Ambulatory Surgery Centers
By Region
· North America
· Europe
· Asia Pacific
· Rest of the World
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com
OR